不同剂量阿斯匹林治疗急性脑梗死的临床分析  

A Clinical Study on Different Doses of Aspirin in the Treatment of Acute Cerebral Infarction

作　　者：李诗海[1] 高继英[1] 刘春安[1] 李德洋[1] 闵敏[1] 周焕明[1] 王拥军[2] 

机构地区：[1]山东省滕州市中心人民医院,277500 [2]首都医科大学宣武医院,100053

出　　处：《中国临床医学》1999年第3期238-240,共3页Chinese Journal of Clinical Medicine

摘　　要：目的：探讨阿斯匹林（ASA）抗血栓的合理剂量。方法：对服用不同首次剂量及不同维持剂量ASA治疗201例急性脑梗死患者、34例脑梗死对照者、26名健康者进行了血浆血栓素B2、6-酮-前列腺素F1a、血小板聚集（PA）率和疗效及不良反应的动态观察。结果：首次用量300mg24hPA率、血浆血栓素B2／6－酮－前列腺素F1a比值明显低于用药前、150mg组及对照组；PA率达健康组水平，与450mg组无显著差异；维持用量100mg较50mg下降明显，PA率保持健康组水平；300／100mg、450／100mg组神经功能改善显著；450／100mg组上消化道反应、大便潜血显著增加。结论：ASA治疗急性脑梗死抗血栓快速、有效和安全，其合理量是首次300mg，维持用量是100mg／d。objective: To find a rational dose of aspirin in the antithrombotic treatment of acute cerebral infarction. Methods: Dynamic observations on plasma TXB2.6 - keto - PGF1a(with radioimmunoassay), platelet aggregation (with turbidmietry), as well as therapeutic effect and side effect were carried out in 201 cases with acute cerebral infarction, who had taken distinct initial doses and distinct maintenance doses of ASA 26 hedthy persons and 34 control cases with cerebral infarction. ResultS: 24 hours after taking the initial dose of ASA 300 mg, the rate of platelet aggregation and the ratio of plasma TXB2/6- Keto - PGF1a were significantly lower than that before taking ASA that of control group the platelet aggregation reached the healthy level or lower, and was lowered more significantly than that of 150 mg groups. The decrese was not significant in compared with that of 450 mg group. The decreases of 100 mg ndnboning for groupe wer more forficant than tha of 50 mg group.The platelet aggregtion of 300/100 tng and 450/100 mg pepe edned on the hedthy level or lower, and nerv function improved sighficanly. The upper digestive tract side effec and sed edt the test in 450/100 mg group increased significantly.Conclusions:The rapidly - acting, effective and safe ASA anitboic ed dritial dose is 300 mg and maintenance dose is 100 mg/d in Acute cerebral infarction.

关 键 词：阿司匹林 脑梗塞 剂量 药物疗法 

分 类 号：R743.330.5[医药卫生—神经病学与精神病学]